AbbVie and Allergan announced Tuesday, March 17, that they signed a consent decree with the US Federal Trade Commission that will commit the companies to selling some properties if they commence a planned merger.
As previously announced, the companies plan to sell brazikumab, an experimental Crohn’s disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé.
Tuesday’s announcement also stated that Nestlé plans to purchase Viokace, a similar product. The companies stated they expect the deal to close in May.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Belgian Authorities Detain Multiple Individuals Over Alleged Huawei Bribery in EU Parliament
Mar 13, 2025 by
CPI
Grubhub’s Antitrust Case to Proceed in Federal Court, Second Circuit Rules
Mar 13, 2025 by
CPI
Pharma Giants Mallinckrodt and Endo to Merge in Multi-Billion-Dollar Deal
Mar 13, 2025 by
CPI
FTC Targets Meta’s Market Power, Calls Zuckerberg to Testify
Mar 13, 2025 by
CPI
French Watchdog Approves Carrefour’s Expansion, Orders Store Sell-Off
Mar 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li